

ReNeuron Group plc
("ReNeuron" or the "Company")

Jefferies 2019 Global Healthcare Conference

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that the Company's management team will be participating in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday 4 June 2019 in New York City.

For further information on the conference, please visit the following link: [Jefferies 2019 Global Healthcare Conference](#)

ENDS

Contacts:

ReNeuron

Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer

+44 (0) 20 3819 8400

Buchanan (UK Media/Investor Relations)

Mark Court, Sophie Wills, Tilly Abraham

+44 (0) 20 7466 5000

Argot Partners (US Media/Investor Relations)

Claudia Styslinger, David Rosen

+1 212 600 1902 or email
claudia@argotpartners.com

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Jonathan Senior, Stewart Wallace, Ben Maddison

+44 (0) 20 7710 7600

N+1 Singer Advisory LLP (Joint Broker)

Aubrey Powell, Mark Taylor

+44 (0) 20 7496 3000

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery

system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.